Bioavailability, Containment and Gene - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

Containment

Gene

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

JUNE 14, 2023

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. The solution of Vevye does not contain water, anti-microbial preservatives, oils or surfactants. Vevye (cyclosporine ophthalmic solution) 0.1

Gene Silencing

Gene Silencing Drug Delivery FDA Approval RNA

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. 3 positive human cells and silence the targeted genes.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

Vevye: A New Cyclosporine Solution for Dry Eye Disease

Cell-penetrating peptides as a delivery system for oligonucleotides

Stay Connected